Fundraising Fox

Progentec

Oklahoma City, US · Founded 2015 · Delaware corporation · 16 employees on LinkedIn · 1 known investors

Progentec develops diagnostic and digital health solutions for autoimmune disease detection and treatment, including biomarker tests and remote monitoring technologies for clinicians and patients. The company focuses on improving health outcomes for the 25 million Americans living with autoimmune diseases.

Founders & leadership

MPMohan Purushothaman
Mohan PurushothamanCEO
MP
Mohan Purushothaman, Ph.D.President, Chairman, & CEO
RS
Robert SaundersNamed on SEC filing
SS
Sanjiv SharmaNamed on SEC filing

Investors · 1

Reported raises · per SEC filings

Form D private placements

$2.5M disclosed across 1 round · 2017

$2.5MraisedNov 2018 · 7 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Robert SaundersDirector
  • Mohan PurushothamanExecutive Officer, Director
  • Sanjiv SharmaExecutive Officer, Director
Offering amount
$2.5M
Amount sold
$2.5M
Minimum investment
$75K
Proceeds to insiders
$150K
First sale
Nov 2017
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06c
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap

Companies competing with Progentec for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2020$1.5M
National Institutes of Health (NIH)National Institutes of HealthPhase I2019$225K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Frequently asked questions

What does Progentec do?
Progentec develops diagnostic and digital health solutions for autoimmune disease detection and treatment, including biomarker tests and remote monitoring technologies for clinicians and patients. The company focuses on improving health outcomes for the 25 million Americans living with autoimmune diseases.
Who are Progentec's investors?
Progentec's investors include Plains Ventures.
How much funding has Progentec raised?
Progentec has disclosed $2.5M raised across 1 round.
Where is Progentec headquartered?
Progentec is headquartered in Oklahoma City, US.